Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.

about

Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.

Item

http://www.wikidata.org/entity/Q47147843

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Co-targeting aurora kinase wit ...... a novel therapeutic strategy.

@en

Co-targeting aurora kinase wit ...... a novel therapeutic strategy.

@nl

type

Item

label

Co-targeting aurora kinase wit ...... a novel therapeutic strategy.

@en

Co-targeting aurora kinase wit ...... a novel therapeutic strategy.

@nl

prefLabel

Co-targeting aurora kinase wit ...... a novel therapeutic strategy.

@en

Co-targeting aurora kinase wit ...... a novel therapeutic strategy.

@nl

P1476

Co-targeting aurora kinase wit ...... a novel therapeutic strategy.

@en

P2093

Bryan Huber

http://www.w3.org/2001/XMLSchema#string

Carla Morales

http://www.w3.org/2001/XMLSchema#string

Catherine Spier

http://www.w3.org/2001/XMLSchema#string

Daruka Mahadevan

http://www.w3.org/2001/XMLSchema#string

Eric Weterings

http://www.w3.org/2001/XMLSchema#string

Laurence Cooke

http://www.w3.org/2001/XMLSchema#string

Shariful Islam

http://www.w3.org/2001/XMLSchema#string

P2860

Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma

IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples

Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression

Drug combination studies and their synergy quantification using the Chou-Talalay method

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.

Update on Aurora Kinase Targeted Therapeutics in Oncology.

P304

100326-100338

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.22222

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eric Vick

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29245981

http://www.w3.org/2001/XMLSchema#string

P932

5725023

http://www.w3.org/2001/XMLSchema#string